Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pleozymes are pleiotropic oxidized carbon nanozymes designed as synthetic redox mediators to enhance the metabolic resilience and persistence of CAR T cell therapies, particularly in solid tumors. These 3-8 nm nanoparticles are synthesized from coconut-derived activated charcoal and exhibit mitochondrial localization. They function by mimicking multiple enzymatic activities, including superoxide dismutase (SOD)-like scavenging and NADH/NAD+ interconversion. By modulating the redox environment, Pleozymes restore bioenergetic flexibility, concurrently activating glycolysis, fatty acid beta-oxidation, and the tricarboxylic acid (TCA) cycle. In preclinical models of hepatocellular carcinoma, treatment with Pleozymes reduced T cell exhaustion markers (TIM-3 and LAG-3) and promoted differentiation into stem cell memory (TSCM) and central memory (TCM) phenotypes, thereby improving antitumor efficacy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pleozymes.